At present, the treatment of AHF is limited to ribavirin and immune plasma [8, 9] . The latter has only been proven to be effective in treating cases of Argentine hemorrhagic fever (Junín virus infection) within 8 days of disease onset. Off-label usage of ribavirin has been shown to be effective in treating Lassa fever when therapy was initiated within 6 days of the development of clinical symptoms. However, there are toxicities associated with ribavirin therapy at dosages required for efficacious use, which may contribute to the observed poor patient compliance in completing prescribed treatment regimens [10, 11] . Very limited case data using ribavirin to treat other AHFs supports the use of emergency protocols [1, 12, 13] , however the utility of ribavirin therapy remains to be seen.